Selective AKT3 Activator Compounds for Precise Treg Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The roles of Akt isoforms in Treg function and induction are not fully understood, and there is a need for compounds and methods to selectively activate Akt3 in immune cells to modulate immune responses.
Innovation Solution
Compositions and methods involving compounds of specific formulas (I-IV) that selectively activate Akt3, including mJJ64A (4-(m-{[p-(4-Pyridylamino)phenylamino]carbonyl}phenylamino)-6-quinolinecarbonitrile, to increase the suppressive function of natural Tregs and induce induced Tregs, thereby modulating immune responses.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If non-selective Akt inhibitors are used to modulate Treg function, then Treg suppressive activity is enhanced, but off-target effects on Akt1 and Akt2 cause unintended immune suppression and loss of anti-tumor immunity
Solution Approach 1:
The patent applies local quality by developing compounds that selectively target Akt3 over Akt1 and Akt2. The molecular structures are designed with specific pharmacological properties that confer preferential binding affinity to Akt3, enabling localized modulation of Akt3 function in Tregs without affecting other Akt isoforms. This selectivity resolves the contradiction by ensuring that immune suppression is achieved through Akt3-specific mechanisms rather than non-specific Akt inhibition.
Solution Approach 2:
The patent utilizes parameter changes by modifying the pharmacological parameters of Akt inhibition through structural optimization of compound formulas. By adjusting molecular weight, binding affinity constants, and selectivity ratios between Akt3 versus Akt1/2, the compounds achieve optimal specificity. This parameter optimization enables reliable Akt3 modulation while minimizing off-target effects on other Akt isoforms.
2Reliability
If Akt3 is selectively activated to enhance Treg function, then immune suppressive responses are increased, but the mechanism remains unclear and requires new compound development
Solution Approach 1:
The patent applies segmentation by dividing the Akt signaling system into isoform-specific modules. Instead of treating Akt as a single unified target, the compounds are designed to selectively activate Akt3 while leaving Akt1 and Akt2 unaffected. This modular approach simplifies the overall mechanism by focusing on one specific Akt isoform at a time, making the complex Akt signaling pathway manageable and targetable through selective pharmacology.
Solution Approach 2:
The patent introduces intermediary compounds that serve as selective activators of Akt3. These compounds act as mediators between the external therapeutic agent and the Akt3 target, transferring the activation signal specifically to Akt3 without directly affecting other cellular pathways. The intermediaries (compounds of Formula I-IV) simplify the complex interaction by providing a controlled, selective mechanism for Akt3 activation.
3Productivity
If existing Akt inhibitors are used, then broad Akt signaling is suppressed, but the lack of isoform specificity results in unpredictable immune responses
Solution Approach 1:
The patent applies parameter changes by optimizing the selectivity parameter of Akt inhibition. The compounds are designed with specific binding affinity constants that favor Akt3 over Akt1 and Akt2. By adjusting parameters such as Kd values and selectivity ratios, the system achieves precise control over which Akt isoform is inhibited, transforming the unpredictable broad suppression into a controlled, precise modulation of Treg function.
Data Source
AI summary
Compositions and methods of selectively activating Akt3 are provided.